Aerovate Therapeutics Inc

NASDAQ AVTE

Download Data

Aerovate Therapeutics Inc Short-Term Debt to Equity Ratio for the quarter ending March 31, 2024: 0.00

Aerovate Therapeutics Inc Short-Term Debt to Equity Ratio is 0.00 for the quarter ending March 31, 2024, a 48.43% change year over year. The short-term debt to equity ratio measures the proportion of short-term debt to shareholders' equity. It is calculated by dividing the short-term debt by the shareholders' equity. This ratio indicates the level of short-term debt relative to the equity invested by shareholders. A higher ratio suggests a higher dependency on short-term debt financing compared to equity financing.
  • Aerovate Therapeutics Inc Short-Term Debt to Equity Ratio for the quarter ending March 31, 2023 was 0.00, a 176.75% change year over year.
  • Aerovate Therapeutics Inc Short-Term Debt to Equity Ratio for the quarter ending March 31, 2022 was 0.00.
NASDAQ: AVTE

Aerovate Therapeutics Inc

CEO Mr. Timothy P. Noyes M.B.A.
IPO Date June 30, 2021
Location United States
Headquarters 930 Winter Street, Waltham, MA, United States, 02116
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email